Kintor Pharmaceutical Limited
KNTPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $819 | $2,500 | $2,500 | $0 |
| % Growth | -67.3% | 0% | – | – |
| Cost of Goods Sold | $2,577 | $4,865 | $4,865 | $42 |
| Gross Profit | -$1,758 | -$2,365 | -$2,365 | -$7,129 |
| % Margin | -214.8% | -94.6% | -94.6% | – |
| R&D Expenses | $5,337 | $39,072 | $39,072 | $774 |
| G&A Expenses | $0 | $30,913 | $30,913 | $27,587 |
| SG&A Expenses | $4,165 | $44,192 | $44,192 | $36 |
| Sales & Mktg Exp. | $0 | $13,279 | $13,279 | $6,975 |
| Other Operating Expenses | $0 | -$13,344 | -$13,344 | $110,002 |
| Operating Expenses | $9,502 | $69,919 | $69,919 | $110,812 |
| Operating Income | -$11,261 | -$72,284 | -$72,284 | -$853 |
| % Margin | -1,375.6% | -2,891.4% | -2,891.4% | – |
| Other Income/Exp. Net | -$168 | -$5,353 | -$5,353 | $5 |
| Pre-Tax Income | -$11,428 | -$77,637 | -$77,637 | -$849 |
| Tax Expense | -$38 | $9 | $9 | $0 |
| Net Income | -$11,390 | -$77,646 | -$77,646 | -$849 |
| % Margin | -1,391.5% | -3,105.8% | -3,105.8% | – |
| EPS | -0.026 | -0.027 | -0.023 | -1.98 |
| % Growth | 2.6% | -17% | 98.8% | – |
| EPS Diluted | -0.026 | -0.027 | -0.023 | -1.98 |
| Weighted Avg Shares Out | 434,071 | 430,724 | 430,724 | 430 |
| Weighted Avg Shares Out Dil | 434,071 | 430,724 | 430,724 | 430 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $2,105 | $2,105 | $605 |
| Interest Expense | $306 | $4,639 | $4,639 | $503 |
| Depreciation & Amortization | $1,732 | $8,814 | $8,814 | $7 |
| EBITDA | -$9,325 | -$64,185 | -$64,185 | -$847 |
| % Margin | -1,139.2% | -2,567.4% | -2,567.4% | – |